Markets

Sarepta Unveils New Phase IIb Eteplirsen Data, Shares Soar

Sarepta Therapeutics, Inc. 's SRPT shares shot up 22.3% after the company announced additional long-term efficacy and safety data from a phase IIb program on its Duchenne muscular dystrophy (DMD) candidate, eteplirsen.

Results showed that patients when treated with eteplirsen demonstrated a statistically significant 151 meter difference in the 6-minute walk test at three years compared to the control arm. Patients on eteplirsen witnessed loss in ambulation at a lower rate than the control arm over three years with pulmonary function remaining relatively stable through four years. Additionally, data from the fourth biopsy established that exon skipping occurred in 100% of patients after 180 weeks of treatment with an increase in dystrophin production in patients who received eteplirsen. On the safety front, eteplirsen was found to be well tolerated with a consistent safety profile.

We note that eteplirsen is the company's lead pipeline candidate and is currently under the priority review in the U.S. with a response expected by Feb 26, 2016. The candidate enjoys Fast Track and orphan status in the U.S. In Aug 2015, eteplirsen also received a rare pediatric disease designation from the FDA for DMD.

Eteplirsen's approval would be a huge boost for the company - it would be able to address about 13% of the total DMD population. However, we note that several companies including BioMarin Pharmaceutical Inc. BMRN are working on bringing DMD treatments to the market. In fact, BioMarin is a step ahead of Sarepta and could gain FDA approval for its DMD candidate, drisapersen, by Dec 27, 2015.

But before that, both eteplirsen and drisapersen will most likely be reviewed by the FDA's Peripheral and Central Nervous System Drugs Advisory Committee in late November. BioMarin would have a head start if approval comes on schedule. The company also received rare pediatric disease status from the FDA for drisapersen.

Sarepta currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the health care sector are Regeneron Pharmaceuticals, Inc. REGN and Endo International plc ENDP , each carrying a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

REGENERON PHARM (REGN): Free Stock Analysis Report

ENDO INTL PLC (ENDP): Free Stock Analysis Report

BIOMARIN PHARMA (BMRN): Free Stock Analysis Report

SAREPTA THERAP (SRPT): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

REGN BMRN SRPT ENDP

Other Topics

Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More